drugset / Trial / NCT07303283
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
Phase 2
Not yet recruiting
140 enrolled
Kai Hu
Affiliated Hospital of Youjiang Medical University for Nationalitie · collabAffiliated Hospital of North Sichuan Medical College · collabFirst People's Hospital of Yulin · collabFujian Cancer Hospital · collabGuangxi Nanxishan Hospital · collabGuigang People's Hospital · collabHainan Cancer Hospital · collabHunan Cancer Hospital · collabLingshan people's Hospital · collabLiuZhou People's Hospital · collabLiuzhou Workers' Hospital · collabThe Third people's hospital of Hechi · collabWuzhou Red Cross Hospital · collabthe second People's Hospital of qinzhou · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to evaluate the efficacy and safety of single-agent Becotatug Vedotin as adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal carcinoma (NPC).
Timeline
- Start
- 2026-09-01
- Primary completion
- 2030-08-31
- Completion
- 2033-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Monoclonal antibody | 2.3 mg/kg | Intravenous |